Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
November 20, 2012 at 21:43 PM EST
Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients
Supernus Pharmaceuticals (NASDAQ: SUPN ) received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multicenter randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnosed with Attention Deficit and Hyperactivity Disorder (ADHD) and
Read More >>
GBL INV HSE
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here